A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy
Abstract Immune checkpoints are crucial for regulating immune responses and maintaining self-tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor immune evasion. This review concentrates on the immune checkpoint molecules PSGL-1 and VISTA. Both molecules are highl...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
BMC
2024-12-01
|
| Series: | Biomarker Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1186/s40364-024-00693-8 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832585482056237056 |
|---|---|
| author | Manqing Peng Xiaofang Lu Junshuang Guo Xiangli Yin Jing Zhang Xin Li Yizhou Zou |
| author_facet | Manqing Peng Xiaofang Lu Junshuang Guo Xiangli Yin Jing Zhang Xin Li Yizhou Zou |
| author_sort | Manqing Peng |
| collection | DOAJ |
| description | Abstract Immune checkpoints are crucial for regulating immune responses and maintaining self-tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor immune evasion. This review concentrates on the immune checkpoint molecules PSGL-1 and VISTA. Both molecules are highly expressed in hematopoietic cells, including T cells and myeloid cells. VISTA functions both as a ligand on myeloid cells, where it regulates cytokine production, chemotaxis, and phagocytosis while promoting their differentiation into a tolerogenic phenotype and as a receptor on T cells, where it contributes to T cell quiescence. PSGL-1, which acts as a binding partner for VISTA, further inhibits T-cell activation and fosters tolerance within the acidic tumor microenvironment. Our review provides a comprehensive analysis of the structure, expression, and biological functions of PSGL-1 and VISTA and emphasizes their therapeutic potential in cancer treatment, autoimmune diseases, and transplantation. The dual role of these checkpoints in immune regulation presents novel opportunities for advancing cancer immunotherapy and developing new strategies for managing autoimmune conditions. |
| format | Article |
| id | doaj-art-302b595b4c304c8d85ec8a0bdb11ab21 |
| institution | Kabale University |
| issn | 2050-7771 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | BMC |
| record_format | Article |
| series | Biomarker Research |
| spelling | doaj-art-302b595b4c304c8d85ec8a0bdb11ab212025-01-26T12:45:43ZengBMCBiomarker Research2050-77712024-12-0112111610.1186/s40364-024-00693-8A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapyManqing Peng0Xiaofang Lu1Junshuang Guo2Xiangli Yin3Jing Zhang4Xin Li5Yizhou Zou6Department of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityDepartment of Immunology, School of Basic Medicine, Central South UniversityAbstract Immune checkpoints are crucial for regulating immune responses and maintaining self-tolerance, as they play a pivotal role in preventing autoimmunity and facilitating tumor immune evasion. This review concentrates on the immune checkpoint molecules PSGL-1 and VISTA. Both molecules are highly expressed in hematopoietic cells, including T cells and myeloid cells. VISTA functions both as a ligand on myeloid cells, where it regulates cytokine production, chemotaxis, and phagocytosis while promoting their differentiation into a tolerogenic phenotype and as a receptor on T cells, where it contributes to T cell quiescence. PSGL-1, which acts as a binding partner for VISTA, further inhibits T-cell activation and fosters tolerance within the acidic tumor microenvironment. Our review provides a comprehensive analysis of the structure, expression, and biological functions of PSGL-1 and VISTA and emphasizes their therapeutic potential in cancer treatment, autoimmune diseases, and transplantation. The dual role of these checkpoints in immune regulation presents novel opportunities for advancing cancer immunotherapy and developing new strategies for managing autoimmune conditions.https://doi.org/10.1186/s40364-024-00693-8VISTAPSGL-1CancerAutoimmune diseasesImmune toleranceImmunotherapy |
| spellingShingle | Manqing Peng Xiaofang Lu Junshuang Guo Xiangli Yin Jing Zhang Xin Li Yizhou Zou A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy Biomarker Research VISTA PSGL-1 Cancer Autoimmune diseases Immune tolerance Immunotherapy |
| title | A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy |
| title_full | A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy |
| title_fullStr | A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy |
| title_full_unstemmed | A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy |
| title_short | A pair of promising immune checkpoints PSGL-1 and VISTA from immunotolerance to immunotherapy |
| title_sort | pair of promising immune checkpoints psgl 1 and vista from immunotolerance to immunotherapy |
| topic | VISTA PSGL-1 Cancer Autoimmune diseases Immune tolerance Immunotherapy |
| url | https://doi.org/10.1186/s40364-024-00693-8 |
| work_keys_str_mv | AT manqingpeng apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xiaofanglu apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT junshuangguo apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xiangliyin apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT jingzhang apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xinli apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT yizhouzou apairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT manqingpeng pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xiaofanglu pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT junshuangguo pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xiangliyin pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT jingzhang pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT xinli pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy AT yizhouzou pairofpromisingimmunecheckpointspsgl1andvistafromimmunotolerancetoimmunotherapy |